Month: February 2021

NEW HAVEN, Conn., Feb. 12, 2021 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that the Company will host a virtual Key Opinion Leader (“KOL”) event on Friday, February 19, 2021 from 11:00 am ET to 2:00 pm ET. The event aims to highlight BXCL501, the Company’s investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine (“Dex”), and its potential as a treatment option for multiple neuropsychiatric conditions.BioXcel’s management team will be joined by leading experts for each indication to discuss the significant unmet medical need and BXCL501’s potential to change the treatment paradigm.KOL...

TORONTO, Feb. 12, 2021 (GLOBE NEWSWIRE) — Routemaster Capital Inc. (the “Company” or “Routemaster”) (NEO: DEFI GR: RMJR) is pleased to announce that it has closed the transaction to acquire 20% of Valour Structured Products (“Valour”), first announced on January 4, 2021 (the “Transaction”). Please see the Company`s press release dated January 4, 2021 for additional information on Valour.Pursuant to the Transaction, Routemaster issued a total of 21,000,000 common shares of the Company to the shareholders of Valour in proportion to their pro rata shareholdings of Valour, in exchange for a 20% interest in Valour. No finder fees were paid connection with, and no change of control of Routemaster resulted from the transaction.Valour Structured Products appoints Diana Biggs, previously Global Head of Innovation at HSBC Private Banking,...

TORONTO, Feb. 12, 2021 (GLOBE NEWSWIRE) — Bunker Hill Mining Corp (the “Company”) (CSE: BNKR) is pleased to announce that it is changing its fiscal year-end to December 31, from its current fiscal year-end of June 30.The Company believes this change of fiscal year-end will better align the Company’s financial reporting periods with industry peers, which will allow investors to more easily compare quarterly and annual financial results.David Wiens, CFO & Corporate Secretary, commented: “As part of the ongoing effort to modernize our management and governance systems, this change of fiscal year-end will align the Company’s financial reporting periods with industry peers, improving both transparency and performance management”.Consistent with regulatory requirements, the Company is planning to file a transition report by March...

ORLANDO, Fla., Feb. 12, 2021 (GLOBE NEWSWIRE) — Gencor Industries, Inc. (Nasdaq: GENC) announced today net revenues of $19.0 million for the quarter ended December 31, 2020 compared to $18.0 million for the quarter ended December 31, 2019.  There were no revenues generated by the Blaw-Knox paver product line during the quarter ended December 31, 2020, as the facility was being readied to begin production. Gross margins were 15.7% for the quarter ended December 31, 2020 compared to 24.0% for the quarter ended December 31, 2019. The gross profit margins for the quarter ended December 31, 2020 were negatively impacted by unabsorbed manufacturing labor and overhead expenses related to the Blaw-Knox paver product line. Excluding these Blaw-Knox expenses, the gross profit margin for the quarter ended December 31, 2020, would have been 23.5%,...

To Nasdaq Copenhagen                                                  12 February 2021Refinancing of floating rate loans.The Nykredit Group has conducted an auction in connection with the refinancing of floating rate loans on 1 April 2021.Enquiries may be addressed to Funding & Capital, Lars Mossing Madsen, tel. +45 44 55 11 66.AttachmentRefinancing of floating rate loans – Nykredit Realkredit – 12022021

Til    Nasdaq Copenhagen                                                                                   12. februar 2021Refinansiering af variabelt forrentede lån.

SALT LAKE CITY, Feb. 12, 2021 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today additional data further validating the prognostic power of its Prolaris® test and its ability to help accurately predict which men with more aggressive prostate cancer will benefit from intensification of therapy and which patients may safely avoid such treatments. This second validation study was presented during an oral presentation at the American Society of Clinical Oncology Genitourinary Cancer Symposium (ASCO-GU) by Jonathan Tward M.D., Ph.D, associate professor in the Department of Radiation Oncology at the University of Utah.According to estimates by the American Cancer Society, 248,530 new cases of prostate cancer are expected to be diagnosed this year in the U.S. While...

VANCOUVER, British Columbia, Feb. 12, 2021 (GLOBE NEWSWIRE) — Neptune Digital Assets Corp. (TSX-V:NDA) (OTC:NPPTF) (FSE:1NW) (“Neptune” or the “Company“) is pleased to announce that the Company is now trading on the TSX-V under the symbol “NDA”. The Company is extremely pleased with the performance of our key holdings over the previous months. Bitcoin, ATOM, Ethereum, Fantom, and Dash continue to advance their projects which is directly reflected in their massive price appreciation, a true testament to the diversified strategy at Neptune.Neptune’s top 5 crypto holdings have rallied as much as 500%+ since our last corporate update, see below:The Company continues to dollar cost average into top tokens which have been deemed as outperformers by Neptune. The focus remains on providing low-cost diversified exposure to cryptocurrency...